Canada Attempts Biosimilar Balancing Act
Executive Summary
Plans to make Canada’s biologics market more competitive for biosimilars are advancing as payers are planning consultations on how price negotiations for biosimilars and biologics will proceed.
You may also be interested in...
Biosimilar Firms Say Irish Price Deal Hinders Uptake, As Govt Plans New Policy Measures
The Irish health ministry is planning measures to boost the prescribing of biosimilar medicines, but companies marketing biosimilars say that the pricing agreement signed last year by the originator industry and the government has served to hinder uptake of their products.
Biosimilars Switching Debate Escalates After Remicade and Remsima Match In Landmark Study
Biosimilar drug makers say that the NOR-SWITCH study on switching from Johnson & Johnson’s infliximab to the Celltrion product supports the concept of biosimilarity and proves that they are subject to the same regulatory standards as originators. Originators, meanwhile, want more evidence that switching works.
Canada Ups Pricing Pressure on Biosimilars And Originators
Manufacturers of biosimilars and originator/reference products are set to come under greater pressure to lower prices in Canada. In order to win reimbursement they will likely have to enter into pricing talks with the pan-Canadian Pharmaceutical Alliance (pCPA), which negotiates drug prices on behalf of Canada's public provincial and territorial drug plans. In a bid to develop a more competitive and transparent market for biosimilars, the pCPA has published its First Principles, aimed at guiding consistent negotiations for both biosimilars and their originator products.